Self-Similar Dynamical Relaxation of Dark Matter Halos in an Expanding Universe

We investigate the structure of cold dark matter halos using advanced models of spherical collapse and accretion in an expanding Universe. These base on solving time-dependent equations for the moments of the phase-space distribution function in the fluid approximation; our approach includes non-radial random motions, and most importantly, an advanced treatment of both dynamical relaxation effects that takes place in the infalling matter: phase-mixing associated to shell crossing, and collective collisions related to physical clumpiness. We find self-similar solutions for the spherically-averaged profiles of mass density rho(r), pseudo phase-space density Q(r) and anisotropy parameter beta(r). These profiles agree with the outcomes of state-of-the-art N-body simulations in the radial range currently probed by the latter; at smaller radii, we provide specific predictions. In the perspective provided by our self-similar solutions we link the halo structure to its two-stage growth history, and propose the following picture. During the early fast collapse of the inner region dominated by a few merging clumps, efficient dynamical relaxation plays a key role in producing a closely universal mass density and pseudo phase-space density profiles; in particular, these are found to depend only weakly on the detailed shape of the initial perturbation and the related collapse times. The subsequent inside-out growth of the outer regions feeds on the slow accretion of many small clumps and diffuse matter; thus the outskirts are only mildly affected by dynamical relaxation but are more sensitive to asymmetries and cosmological variance.Comment: 31 pages, 16 figures. Typos corrected. Accepted by Ap

The joint evolution of baryons and dark matter haloes

We have studied the dark matter (DM) distribution in a approx 10^12 h^-1 M_sun mass halo extracted from a simulation consistent with the concordance cosmology, where the physics regulating the transformation of gas into stars was allowed to change producing galaxies with different morphologies. The presence of baryons produces the concentration of the DM halo with respect to its corresponding dissipationless run, but we found that this response does not only depend on the amount of baryons gathered in the central region but also on the way they have been assembled. DM and baryons affect each other in a complex way so the formation history of a galaxy plays an important role on its final total mass distribution. Supernova (SN) feedback regulates the star formation and triggers galactic outflows not only in the central galaxy but also in its satellites. Our results suggest that, as the effects of SN feedback get stronger, satellites get less massive and can even be more easily disrupted by dynamical friction, transferring less angular momentum. We found indications that this angular momentum could be acquired not only by the outer part of the DM halo but also by the inner ones and by the stellar component in the central galaxy. The latter effect produces stellar migration which contributes to change the inner potential well, probably working against further DM contraction. As a consequence of the action of these processes, when the halo hosts a galaxy with an important disc structure formed by smooth gas accretion, it is more concentrated than when it hosts a spheroidal system which experienced more massive mergers and interactions. (abridged)Comment: 16 pages, 16 figures, accepted to MNRA

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis

none14noWe retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.openVincenzi B.; Nannini M.; Fumagalli E.; Bronte G.; Frezza A.M.; De Lisi D.; Ceruso M.S.; Santini D.; Badalamenti G.; Pantaleo M.A.; Russo A.; Dei Tos A.P.; Casali P.; Tonini G.Vincenzi, B.; Nannini, M.; Fumagalli, E.; Bronte, G.; Frezza, A. M.; De Lisi, D.; Ceruso, M. S.; Santini, D.; Badalamenti, G.; Pantaleo, M. A.; Russo, A.; Dei Tos, A. P.; Casali, P.; Tonini, G

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level

A review of elliptical and disc galaxy structure, and modern scaling laws

A century ago, in 1911 and 1913, Plummer and then Reynolds introduced their models to describe the radial distribution of stars in `nebulae'. This article reviews the progress since then, providing both an historical perspective and a contemporary review of the stellar structure of bulges, discs and elliptical galaxies. The quantification of galaxy nuclei, such as central mass deficits and excess nuclear light, plus the structure of dark matter halos and cD galaxy envelopes, are discussed. Issues pertaining to spiral galaxies including dust, bulge-to-disc ratios, bulgeless galaxies, bars and the identification of pseudobulges are also reviewed. An array of modern scaling relations involving sizes, luminosities, surface brightnesses and stellar concentrations are presented, many of which are shown to be curved. These 'redshift zero' relations not only quantify the behavior and nature of galaxies in the Universe today, but are the modern benchmark for evolutionary studies of galaxies, whether based on observations, N-body-simulations or semi-analytical modelling. For example, it is shown that some of the recently discovered compact elliptical galaxies at 1.5 < z < 2.5 may be the bulges of modern disc galaxies.Comment: Condensed version (due to Contract) of an invited review article to appear in "Planets, Stars and Stellar Systems"(www.springer.com/astronomy/book/978-90-481-8818-5). 500+ references incl. many somewhat forgotten, pioneer papers. Original submission to Springer: 07-June-201

Chromosomal aberrations and aneuploidy in oral potentially malignant lesions: distinctive features for tongue

<p>Abstract</p> <p>Background</p> <p>The mucosae of the oral cavity are different at the histological level but appear all equally exposed to common genotoxic agents. As a result of this exposure, changes in the mucosal epithelia may develop giving rise to Oral Potentially Malignant Lesions (OPMLs), which with time may in turn progress to Oral Squamous Cell Carcinomas (OSCCs). Therefore, much effort should be devoted to identify features able to predict the likeliness of progression associated with an OPML. Such features may be helpful in assisting the clinician to establish both appropriate therapies and follow-up schedules. Here, we report a pilot study that compared the occurrence of DNA aneuploidy and chromosomal copy number aberrations (CNAs) in the OPMLs from different oral anatomical subsites.</p> <p>Methods</p> <p>Samples from histologically diagnosed OPMLs were processed for high resolution DNA flow cytometry (hr DNA-FCM) in order to determine the relative DNA content expressed by the DNA index (DI). Additionally, array-Comparative Genomic Hybridization (a-CGH) analysis was performed on DNA obtained from diploid nuclei suspensions directly. When aneuploid nuclei were detected, these were physically separated from diploid nuclei on the base of their DI values by means of a DNA-FCM-Sorter in order to improve the a-CGH analysis.</p> <p>Results</p> <p>Tongue OPMLs were more frequently associated with DNA aneuploidy and CNAs than OPMLs arising from all the other mucosal subsites.</p> <p>Conclusions</p> <p>We suggest that the follow-up and the management of the patients with tongue OPMLs should receive a distinctive special attention. Clearly, this hypothesis should be validated in a prospective clinical study.</p

Non--power law behavior of the radial profile of phase--space density of halos

We study the pseudo phase-space density, $\rho(r)/\sigma^3(r)$, of $\Lambda$CDM dark matter halos with and without baryons (baryons+DM, and pure DM), by using the model introduced in Del Popolo (2009), which takes into account the effect of dynamical friction, ordered and random angular momentum, baryons adiabatic contraction and dark matter baryons interplay. We examine the radial dependence of $\rho(r)/\sigma^3(r)$ over 9 orders of magnitude in radius for structures on galactic and cluster of galaxies scales. We find that $\rho(r)/\sigma^3(r)$ is approximately a power-law only in the range of halo radius resolved by current simulations (down to 0.1% of the virial radius) while it has a non-power law behavior below the quoted scale, with inner profiles changing with mass. The non-power-law behavior is more evident for halos constituted both of dark matter and baryons while halos constituted just of dark matter and with angular momentum chosen to reproduce a Navarro-Frenk-White (NFW) density profile, are characterized by an approximately power-law behavior. The results of the present paper lead to conclude that density profiles of the NFW type are compatible with a power-law behavior of $\rho(r)/\sigma^3(r)$, while those flattening to the halo center, like those found in Del Popolo (2009) or the Einasto profile, or the Burkert profile, cannot produce radial profile of the pseudo-phase-space density that are power-laws at all radii. The results argue against universality of the pseudo phase-space density and as a consequence argue against universality of density profiles constituted by dark matter and baryons as also discussed in Del Popolo (2009).Comment: 20 pages; 7 figs. arXiv admin note: substantial text overlap with arXiv:0906.4447 and arXiv:1012.432

Globular cluster systems and galaxy formation

Globular clusters are compact, gravitationally bound systems of up to a million stars. The GCs in the Milky Way contain some of the oldest stars known, and provide important clues to the early formation and continuing evolution of our Galaxy. More generally, GCs are associated with galaxies of all types and masses, from low-mass dwarf galaxies to the most massive early-type galaxies which lie in the centres of massive galaxy clusters. GC systems show several properties which connect tightly with properties of their host galaxies. For example, the total mass of GCs in a system scales linearly with the dark matter halo mass of its host galaxy. Numerical simulations are at the point of being able to resolve globular cluster formation within a cosmological framework. Therefore, GCs link a range of scales, from the physics of star formation in turbulent gas clouds, to the large-scale properties of galaxies and their dark matter. In this Chapter we review some of the basic observational approaches for GC systems, some of their key observational properties, and describe how GCs provide important clues to the formation of their parent galaxies.Comment: 32 pages, 6 figures. Accepted for publication in the book "Reviews in Frontiers of Modern Astrophysics: From Space Debris to Cosmology" (eds Kabath, Jones and Skarka; publisher Springer Nature) funded by the European Union Erasmus+ Strategic Partnership grant "Per Aspera Ad Astra Simul" 2017-1-CZ01-KA203-03556

Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer

Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions from June 2014 to June 2020, we studied whether patients on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free survival (PFS). We used targeted transcriptomics in a subset of patients to explore differences in the tumor microenvironment (TME) of patients with or without diabetes. Results: A total of 1,395 patients were included. Primary tumors included non–small cell lung cancer (NSCLC; 54.7%), melanoma (24.7%), renal cell (15.0%), and other carcinomas (5.6%). After multivariable analysis, patients on GLM (n = 226, 16.2%) displayed an increased risk of death [HR, 1.29; 95% confidence interval (CI),1.07–1.56] and disease progression/death (HR, 1.21; 95% CI, 1.03–1.43) independent of number of GLM received. We matched 92 metformin-exposed patients with 363 controls and 78 patients on other oral GLM or insulin with 299 control patients. Exposure to metformin, but not other GLM, was associated with an increased risk of death (HR, 1.53; 95% CI, 1.16–2.03) and disease progression/ death (HR, 1.34; 95% CI, 1.04–1.72). Patients with T2DM with higher pretreatment glycemia had higher neutrophil-to-lymphocyte ratio (P = 0.04), while exploratory tumoral transcriptomic profiling in a subset of patients (n = 22) revealed differential regulation of innate and adaptive immune pathways in patients with T2DM. Conclusions: In this study, patients on GLM experienced worse outcomes from immunotherapy, independent of baseline features. Prospective studies are warranted to clarify the relative impact of metformin over a preexisting diagnosis of T2DM in influencing poorer outcomes in this population